Dotto-Vasquez Giuseppe, Villacorta-Ampuero Andrea K, Ulloque-Badaracco Juan R, Hernandez-Bustamante Enrique A, Alarcón-Braga Esteban A, Herrera-Añazco Percy, Benites-Zapata Vicente A, Hernandez Adrian V
Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.
Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional de Trujillo, Trujillo 13011, Peru.
Diagnostics (Basel). 2022 Nov 1;12(11):2655. doi: 10.3390/diagnostics12112655.
Lymphocyte-to-Monocyte ratio (LMR) has shown an association with survival outcomes in several oncological diseases. This study aimed to evaluate the association between LMR and clinical outcomes for cholangiocarcinoma patients. A systematic review and meta-analysis were performed to assess the association between LMR values and overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS) and time to recurrence (TTR) in cholangiocarcinoma patients. We used Hazard ratio (HR) and their 95% confidence interval (CI) as a measure of effect for the random effect model meta-analysis. The Newcastle-Ottawa Scale was used for quality assessment. The Egger test and funnel plot were developed for approaching publication bias. A total of 19 studies were included in this study (n = 3860). The meta-analysis showed that cholangiocarcinoma patients with low values of LMR were associated with worse OS (HR: 0.82; 95% CI: 0.71-0.96; I = 86%) and worse TTR (HR: 0.71; 95% CI: 0.58-0.86; I = 0%). DFS and RFS also were evaluated; however, they did not show statistically significant associations. Low LMR values were associated with a worse OS and TTR.
淋巴细胞与单核细胞比值（LMR）已显示出与多种肿瘤疾病的生存结果相关。本研究旨在评估LMR与胆管癌患者临床结果之间的关联。我们进行了一项系统评价和荟萃分析，以评估LMR值与胆管癌患者的总生存期（OS）、无病生存期（DFS）、无复发生存期（RFS）和复发时间（TTR）之间的关联。我们使用风险比（HR）及其95%置信区间（CI）作为随机效应模型荟萃分析的效应量度。采用纽卡斯尔-渥太华量表进行质量评估。采用Egger检验和漏斗图来评估发表偏倚。本研究共纳入19项研究（n = 3860）。荟萃分析表明，LMR值较低的胆管癌患者的总生存期较差（HR：0.82；95%CI：0.71 - 0.96；I² = 86%），复发时间也较差（HR：0.71；95%CI：0.58 - 0.86；I² = 0%）。我们还评估了DFS和RFS；然而，它们未显示出统计学上的显著关联。低LMR值与较差的总生存期和复发时间相关。
